227 related articles for article (PubMed ID: 32735752)
1. Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial.
Slagter AE; Sikorska K; Grootscholten C; van Laarhoven HWM; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; van de Velde CJH; van Grieken NCT; van Sandick JW; Jansen EPM; Verheij M; Cats A
Cancer Med; 2020 Sep; 9(18):6609-6616. PubMed ID: 32735752
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Rollins KE; Peters CJ; Safranek PM; Ford H; Baglin TP; Hardwick RH
Eur J Surg Oncol; 2011 Dec; 37(12):1072-7. PubMed ID: 21925829
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Khanna A; Reece-Smith AM; Cunnell M; Madhusudan S; Thomas A; Bowrey DJ; Parsons SL
Dis Esophagus; 2014 Apr; 27(3):242-7. PubMed ID: 23651074
[TBL] [Abstract][Full Text] [Related]
5. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy.
Marshall-Webb M; Bright T; Price T; Thompson SK; Watson DI
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27878904
[TBL] [Abstract][Full Text] [Related]
7. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection.
Boone BA; Zenati MS; Rieser C; Hamad A; Al-Abbas A; Zureikat AH; Hogg ME; Neal MD; Zeh HJ
Ann Surg Oncol; 2019 May; 26(5):1503-1511. PubMed ID: 30652227
[TBL] [Abstract][Full Text] [Related]
8. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
9. Predictive factors of thromboembolic complications in patients with esophagogatric adenocarcinoma undergoing preoperative chemotherapy.
Papaxoinis G; Kamposioras K; Germetaki T; Weaver JMJ; Stamatopoulou S; Nasralla M; Kordatou Z; Owen-Holt V; Anthoney A; Mansoor W
Acta Oncol; 2018 Jun; 57(6):790-798. PubMed ID: 29308947
[TBL] [Abstract][Full Text] [Related]
10. High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
Fehr M; Hawle H; Hayoz S; Thuss-Patience P; Schacher S; Riera Knorrenschild J; Dürr D; Knoefel WT; Rumpold H; Bitzer M; Zweifel M; Samaras P; Mey U; Küng M; Winterhalder R; Eisterer W; Hess V; Gérard MA; Templeton A; Stahl M; Ruhstaller T; ; ; ;
BMC Cancer; 2020 Feb; 20(1):166. PubMed ID: 32111181
[TBL] [Abstract][Full Text] [Related]
11. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
12. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.
Claassen YHM; Hartgrink HH; Dikken JL; de Steur WO; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Meershoek-Klein Kranenbarg WM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Eur J Surg Oncol; 2018 May; 44(5):613-619. PubMed ID: 29503129
[TBL] [Abstract][Full Text] [Related]
13. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
14. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
Brenner B; Shah MA; Karpeh MS; Gonen M; Brennan MF; Coit DG; Klimstra DS; Tang LH; Kelsen DP
Ann Oncol; 2006 Sep; 17(9):1404-11. PubMed ID: 16788003
[TBL] [Abstract][Full Text] [Related]
16. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
[No Abstract] [Full Text] [Related]
17. Venous thromboembolism in advanced ovarian cancer patients undergoing frontline adjuvant chemotherapy.
Pant A; Liu D; Schink J; Lurain J
Int J Gynecol Cancer; 2014 Jul; 24(6):997-1002. PubMed ID: 24905613
[TBL] [Abstract][Full Text] [Related]
18. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210).
Iwasaki Y; Sasako M; Yamamoto S; Nakamura K; Sano T; Katai H; Tsujinaka T; Nashimoto A; Fukushima N; Tsuburaya A;
J Surg Oncol; 2013 Jun; 107(7):741-5. PubMed ID: 23400787
[TBL] [Abstract][Full Text] [Related]
20. The risk of venous thromboembolism after surgery for esophagogastric malignancy and the impact of chemotherapy: a population-based cohort study.
Adiamah A; Ban L; West J; Humes DJ
Dis Esophagus; 2020 Jun; 33(6):. PubMed ID: 31617892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]